Previous Close | 1.9300 |
Open | 1.9700 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 1.8090 - 1.9700 |
52 Week Range | 1.0800 - 26.4000 |
Volume | |
Avg. Volume | 103,572 |
Market Cap | 5.711M |
Beta (5Y Monthly) | 1.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8300 |
Earnings Date | May 08, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.00 |
Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The Plaza Hotel in New York.Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer, Richard Kenney, M.D., Chief Medical Officer, and Jay Cross, Chief Financial Officer, will be presenting on May 15th
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical ...
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability of SON-080 was consistent with data from previous ...